New 3-in-1 hepatitis C treatment will double rate of recovery: NTU
The China Post news staff
May 25, 2014, 12:01 am TWN
TAIPEI, Taiwan -- The new three-in-one hepatitis C treatment could double the recovery rate for patients who have never been treated for the disease, National Taiwan University College of Medicine announced yesterday.
According to the statistics on hepatitis C, there are about 600,000 hepatitis C carriers in Taiwan, but about 90 percent of them have not received medical treatment.
Based on a research conducted by experts in Taiwan, if hepatitis C carriers do not receive medical treatment, their incidence rates of suffering from cirrhosis are 8.3 times higher than cured hepatitis C carriers.
Kao Jia-horng, professor and director of National Taiwan University College of Medicine's Graduate Institute of Clinical Medicine, said that the new three-in-one treatment that combines direct-acting antiviral agents (DAA), interferon and ribavirin, which could stop the replication of the hepatitis virus and increase the recovery rates for hepatitis C carriers.
For hepatitis C patients who have received medical treatment that failed, Kao said that the new three-in-one treatment could triple the recovery rates for those patients.